Demir, Tevfik
Simsir, Ilgin Yildirim
Tuncel, Ozlem Kuman
Ozbaran, Burcu
Yildirim, Ilker
Pirildar, Sebnem
Ozen, Samim
Akinci, Baris http://orcid.org/0000-0002-8634-4845
Funding for this research was provided by:
Amryt Pharma (sponsored study)
Article History
Received: 24 July 2023
Accepted: 19 December 2023
First Online: 5 January 2024
Declarations
:
: The protocol was reviewed and approved by Ethics Committees (EC) and authorized by the Ministry of Health Turkish Medicines and Medical Devices Agency (MoH TMMDA). The original protocol was approved by the EC on 28.12.2017 and then authorized by the MoH on 17.01.2018. All participants gave signed informed consent.
: The protocol was reviewed and approved by Ethics Committees (EC) and authorized by the Ministry of Health Turkish Medicines and Medical Devices Agency (MoH TMMDA). Informed consent was taken from all participants.
: TD, SO, and BA received fees from Amryt Pharmaceuticals. SO has advised Amryt Pharmaceuticals, AbbVie, Rhythm Pharmaceuticals, Novo Nordisk, Sandoz, and Pfizer. OK reports a contract with Fresenius Medical Care for a study. Dr Akinci run projects for and/or served as a consultant, board member, steering committee member, and/or speaker to Amryt, Regeneron, ThirdRock Ventures, Anylham, Astra Zeneca, Novonordisk, Boehringer Ingelheim, Sanofi, Bilim Ilac, ARIS, and Servier. Dr Akinci is a member of the executive board of the European Lipodystrophy Consortium. Other authors report no conflicts of interest.